←
BackTable Tumor Board342 posts
BackTable Tumor Board avatar

BackTable Tumor Board

@_backtableONC

A multidisciplinary podcast for healthcare professionals who provide cancer care!

◷ Joined November 2024▧ 98 Photos and videos
BackTable Tumor Board avatar
BackTable Tumor Board@_backtableONC·1m

A solitary lung metastasis five years after surgery and four liver metastases six months after surgery are two different diseases. Dr. Adam Yopp and Dr. Arsen Osipov (@DrArsenOsipov) tell Dr. Andrew Hendifar (@DrHendifar) why both cases belong back at the multidisciplinary table, and how same-day clinics speed every pancreatic cancer decision. Watch the full episode on the BackTable App: backtable.com/shows/tumor-bo… #ONC92 #PancreaticCancer #TumorBoard #GIOncology #CreatorWeekend @CedarsSinai @UTSWMedCenter

Toni Choueiri, MD avatar
⟳ BackTable Tumor Board retweeted
Toni Choueiri, MD@DrChoueiri·Nov 12

JUST IN: @AmericanCancer (ACS) updates their guidance about routine PSA screening for #prostatecancer, moving off "shared decision-making". This is a major shift since the last ACS recommendations in 2010: 1) High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69 2) Average risk: PSA every 2 years, ages 50–69. American Cancer Society 3) Non-Black men with 1 first-degree relative diagnosed ≥65: PSA every 2 years, ages 45–69. 4) Age 70–74: individualized decision; if screening continues, every 2 years. 5) Age ≥75: generally no screening; very healthy men 75–79 may discuss continued screening. 6) No screening ≥80 and no screening at any age with life expectancy <10 years. @CACancerJournal @DanaFarber_GU @harvardmed @OpenMedInsights Link: acsjournals.onlinelibrary.wi…

Post attachmentPost attachment
Ruchika Talwar avatar
⟳ BackTable Tumor Board retweeted
Ruchika Talwar@RuchikaTalwarMD·Nov 13

Thank you @uretericbud for giving this @_backtableUro episode a listen! I truly believe healthcare feels so *broken* bc of misaligned incentives Docs - let’s keep the patient at the center of our care model and take back control with direct contracting! Even @mcuban says so!!!

I now got a chance to listen carefully to this @_backtableUro episode 1. this is a must listen for anyone even remotely interested in understanding the financial forces of modern medicine 2. @RuchikaTalwarMD is a real pro and the House of Urology should be extremely proud she is representing us on this larger stage 3. @mcuban’s drive and early success in taming the seemingly untamable are extremely refreshing.

BackTable Tumor Board avatar
BackTable Tumor Board@_backtableONC·Nov 12

Generic imatinib, labeled a “specialty” drug in one pharmacy benefit contract Mark Cuban (@mcuban) reviewed, at a price high enough to keep the rebate. At Cost Plus Drugs (@costplusdrugs), he says, 100 tablets run about $21. On Episode 91, he and Dr. Ruchika Talwar (@RuchikaTalwarMD) dig into how contract fine print, not the posted price, decides what cancer care really costs. Watch the full episode on the BackTable App: backtable.com/shows/tumor-bo… #ONC91 #MarkCuban #PBM #DrugPricing #CancerCare #Oncology

Dr Rishabh Jain avatar
⟳ BackTable Tumor Board retweeted
Dr Rishabh Jain@DrRishabhOnco·Nov 11

You cannot be a great oncologist without a deep understanding of immunology. Cancer is not just a disease of mutated cells. It is also a battle between tumors and the immune system. From checkpoint inhibitors to CAR-T cells, modern oncology is increasingly built on immunology. Yet immunology remains underemphasized in oncology training. It’s time to make advanced immunology a mandatory pillar of oncology education.

BackTable Urology avatar
⟳ BackTable Tumor Board retweeted
BackTable Urology@_backtableUro·Nov 10

This guest needs no introduction. 🦈 Mark Cuban joins Dr. Ruchika Talwar to talk about American healthcare, what led him to start Cost Plus Drugs, and what it takes to change how prescription drugs are priced. 🎧 Coming Nov 12 to BackTable Urology & BackTable Industry in the BackTable app. #BackTablePodcast #MarkCuban #CostPlusDrugs #DrugPricing #Healthcare

0:39
BackTable Tumor Board avatar
BackTable Tumor Board@_backtableONC·Nov 10

Run the clinical trial first and save the KRAS inhibitor for later? Dr. Arsen Osipov (@DrArsenOsipov) explains why that order may keep more doors open in metastatic pancreatic cancer, with Dr. Daniel Ahn and Dr. Andrew Hendifar (@DrHendifar). Watch the full episode on the BackTable App: backtable.com/shows/tumor-bo… #ONC90 #PancreaticCancer #KRAS #ClinicalTrials #CreatorWeekend @MayoClinic @CedarsSinai @ASCO @NCCN

BackTable Tumor Board avatar
BackTable Tumor Board@_backtableONC·Nov 9

With most resected pancreatic cancers expected to recur, RAS inhibitors are moving from metastatic disease into the adjuvant setting. Dr. Daniel Ahn outlines the RASolute 304 trial of daraxonrasib versus observation after perioperative chemotherapy, and Dr. Arsen Osipov (@DrArsenOsipov) explains why neoadjuvant use and resistance are the next open questions, in a discussion led by Dr. Andrew Hendifar (@DrHendifar) that ends on how circulating tumor DNA can, and cannot, guide surveillance. Watch the full episode here: backtable.com/shows/tumor-bo… #ONC89 #PancreaticCancer #KRAS #ctDNA #ClinicalTrials #GIOncology #CreatorWeekend @MayoClinic @CedarsSinai @ASCO @NCCN

6:36
BackTable Tumor Board avatar
BackTable Tumor Board@_backtableONC·Nov 7

🧐👀 What do y’all have up your sleeves over there? @_backtableUro @_backtableIND

We’ve got a surprise guest coming to the #BackTablePodcast. 👤 @RuchikaTalwarMD is taking off her clinical hat to talk about the business side of healthcare. Any guesses who it might be? Drop your guess in the comments below. 👇 🎧 Dropping November 12 on BackTable Urology and BackTable Industry. #BackTable #DirectContracting #HealthcareBusiness

Post attachment
Samuel Hume avatar
⟳ BackTable Tumor Board retweeted
Samuel Hume@DrSamuelBHume·Nov 4

Top indications for global cancer vaccine trials: 1. Melanoma (263) 2. Lung cancer (216) 3. Breast cancer (176) Particularly exciting to me are the cancer interception studies (aiming to prevent progression from pre-cancer to cancer) — there are 51 of those, globally.

Post attachment

We mapped the global landscape of cancer vaccine clinical trials. There are 1689 ongoing programs: 640 in phase 1, 786 in phase 2, and 101 in phase 3. Most of them are funded by US institutions (601 trials), followed by China (215) and Japan (141). The top indications are melanoma (263), followed by lung cancer (216) and breast cancer (176). The most common companion immunotherapy is the PD1 inhibitor, pembrolizumab, but some trials test next-gen immunotherapies, including PD1/VEGF and PDL1/TGF-β bispecifics. The full analysis is here: breakthrough.elabela.co/p/th…

Post attachment
LUNGevity Foundation avatar
⟳ BackTable Tumor Board retweeted
LUNGevity Foundation@LUNGevity·Nov 2

Anyone with lungs can get lung cancer. Everyone can make a difference. It is important to share "anyone with lungs can get lung cancer" because lung cancer can affect people of all ages, genders, ethnicities, and past smoking histories. Not recognizing that anyone with lungs can get lung cancer can lead to a delay in diagnosis. How can you help? Share this post with family and friends. And ask them to share it, too. Together we can spread awareness that #AnyoneWithLungs can get lung cancer. For more ideas on how you can make an impact this November, visit lungevity.org/LCAM

Post attachmentPost attachment
BackTable ENT & Allergy avatar
⟳ BackTable Tumor Board retweeted
BackTable ENT & Allergy@_backtableENT·Nov 4

For a child treated for a brain tumor, a cochlear implant and ongoing MRI surveillance can pull in opposite directions. Hear how Dr. Daniela Carvalho (@Dr_D_Carvalho) and Dr. Julie Silva of @radychildrens weigh it, with host Dr. Anthony Sheyn (@AnthonySheyn). Watch the full episode on the BackTable App: backtable.com/shows/ent/podc… #ENT301 #PediatricHearingLoss #Ototoxicity #ChildhoodCancer #CochlearImplant #PediatricENT @UCSDHealth @LeBonheurChild @StJudeResearch @SENTAC1

BackTable Urology avatar
⟳ BackTable Tumor Board retweeted
BackTable Urology@_backtableUro·Nov 4

“Son, have you ever had a cystoscopy?” A patient’s question sums up why intermediate-risk bladder cancer care should be judged by quality of life. Dr. Wesley Yip (@WesleyYipMD) of City of Hope (@cityofhope) and Dr. Ruchika Talwar (@RuchikaTalwarMD) on rethinking intermediate-risk NMIBC. Watch the full episode on the BackTable App: backtable.com/shows/urology/… #URO340 #BladderCancer #NMIBC #Urology #Cystoscopy @AmerUrological @VUMCDiscoveries

BackTable Tumor Board avatar
BackTable Tumor Board@_backtableONC·Nov 4

Can circulating tumor DNA flag a pancreatic cancer recurrence before the scan does, and if it rises, should treatment start? Drs. Arsen Osipov (@DrArsenOsipov) , Daniel Ahn, and Andrew Hendifar (@DrHendifar) on neoadjuvant chemotherapy, pathologic response, prehabilitation, adjuvant RAS inhibitors, and ctDNA. Watch the full episode on the BackTable App: backtable.com/shows/tumor-bo… #ONC89 #PancreaticCancer #GIOncology #KRAS #CreatorWeekend @MayoClinic @CedarsSinai @ASCO @NCCN

BackTable Tumor Board avatar
BackTable Tumor Board@_backtableONC·Nov 1

How do you approach multifocal hepatocellular carcinoma (HCC) in a patient without underlying cirrhosis? This week’s Case Highlight features Drs. Gabriel Schnickel, Adam Burgoyne, Heather Patton (@Pattonhm1), Siddharth Padia (@SidpadiaIR), and Zach Berman (@ZTBerman) discussing multidisciplinary treatment considerations for multifocal HCC in a non-cirrhotic patient, including surgical and non-surgical options. Explore this case and more clinical discussions in the BackTable App: backtable.com/shows/tumor-bo… #HCC #LiverCancer #InterventionalOncology #HepatobiliarySurgery @UCSDCancer